FR

PrCasirivimab and imdevimab for injection

Casirivimab and imdevimab for injection are authorized under the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19.

Solution for infusion, each available as 1332 mg/11.1 mL and 300 mg/2.5 mL (120mg/mL) single-use vials

Anti-SARS-CoV-2 spike protein monoclonal antibodies

DIN 02516705
(1332 mg/11.1 mL)

DIN 02516691
(300 mg /2.5 mL)

For more information, please see below to be redirected to:

Product Monograph Healthcare Professional Letter Patient Medication Information Canadian Reference Labels

This website is neither intended nor designed to record or report adverse event information. If you have a suspected side effect or problem to report regarding a Roche product, please email mississauga.canada_medinfo@roche.com or call 1-888-762-4388. You can also report adverse events relating to any product to Health Canada directly by going to the Canada Vigilance Program website at https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting or call 1-866-234-2345.

The Health Canada product complaint form can be found at this link: https://healthycanadians.gc.ca/apps/radar/MD-IM-0005.08.html

For more information or to report adverse events, please contact us